Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161515 | 0.85 | EPHX1 (0.39) | HSD17B10HPGDSMN1; SMN2EPHX1NPC1 | |
| SCHEMBL29126180 | 0.84 | HSD17B10 (0.39) | HSD17B10HPGDSMN1; SMN2RIPK1EPHX1 | |
| SCHEMBL28890612 | 0.79 | HPGD (0.37) | HSD17B10HPGDRIPK1EPHX1LMNA | |
| SCHEMBL29126207 | 0.78 | HPGD (0.40) | HSD17B10HPGDRIPK1EPHX1LMNA | |
| SCHEMBL5161584 | 0.74 | HSD17B10 (0.39) | HSD17B10HPGDSMN1; SMN2RIPK1EPHX1 | |
| SCHEMBL28906194 | 0.73 | RIPK1 (0.34) | HSD17B10HPGDRIPK1BTKLMNA | |
| SCHEMBL11932167 | 0.71 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL750515 | 0.71 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2NPC1LMNACYP2C19 | |
| SCHEMBL2428695 | 0.71 | DPP4 (0.39) | HSD17B10LMNACYP2C19ALDH1A1 | |
| SCHEMBL28209789 | 0.71 | DPP4 (0.39) | HSD17B10LMNACYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | HSD17B10 3097/4885HPGD 4377/4885SMN1; SMN2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.